Drug Trial Radar · NCT02882984
Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
Last checked: Nov 19, 2026Latest source record: Aug 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
325
Planned (sponsor's estimate)
Start
Mar 2015
Primary completion
Mar 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- Sichuan Provincial People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center phase III randomized controlled study to evaluate the efficacy of Hypofractionated SRS (HFSRS) along with EGFR-TKI in patients with brain metastasis from non-small cell lung cancer (NSCLC). Assuming that HFSRS is not inferior to EGFR-TKI concurrent with whole brain radiotherapy (WBRT), the primary end point is intracranial PFS (iPFS), while secondary outcomes included overall survival (OS), evaluation of cognitive function, quality of life (QoL) and adverse events.
Conditions
- Stage IV EGFR Mutated NSCL With Brain Metastases
Interventions
Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/IcotinibDrug
radiation given along with one of kind TKI
WBRTRadiation
3750 cGy in 15 fractions given within 3 weeks time.
HFSRSRadiation
All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- iPFSTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan PPH, Cancer Center
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.